WallStSmart

Diebold Nixdorf, Incorporated (DBD)vsServiceNow Inc (NOW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ServiceNow Inc generates 262% more annual revenue ($13.96B vs $3.86B). NOW leads profitability with a 12.6% profit margin vs 2.8%. DBD trades at a lower P/E of 29.0x. DBD earns a higher WallStSmart Score of 56/100 (C).

DBD

Buy

56

out of 100

Grade: C

Growth: 6.7Profit: 5.5Value: 5.3Quality: 5.0
Piotroski: 4/9Altman Z: 1.57

NOW

Buy

54

out of 100

Grade: C-

Growth: 7.3Profit: 6.0Value: 6.0Quality: 5.0
Piotroski: 1/9Altman Z: 1.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DBD.

NOWUndervalued (+83.0%)

Margin of Safety

+83.0%

Fair Value

$605.51

Current Price

$103.24

$502.27 discount

UndervaluedFair: $605.51Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DBD2 strengths · Avg: 9.0/10
EPS GrowthGrowth
815.0%10/10

Earnings expanding 815.0% YoY

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

NOW4 strengths · Avg: 8.5/10
Market CapQuality
$112.25B9/10

Large-cap with strong market position

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
22.1%8/10

Revenue surging 22.1% year-over-year

Free Cash FlowQuality
$1.53B8/10

Generating 1.5B in free cash flow

Areas to Watch

DBD4 concerns · Avg: 3.5/10
P/E RatioValuation
29.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.574/10

Distress zone — elevated risk

Profit MarginProfitability
2.8%3/10

2.8% margin — thin

Debt/EquityHealth
1.073/10

Elevated debt levels

NOW4 concerns · Avg: 3.8/10
Price/BookValuation
9.1x4/10

Trading at 9.1x book value

EPS GrowthGrowth
2.3%4/10

2.3% earnings growth

Altman Z-ScoreHealth
1.654/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DBD

The strongest argument for DBD centers on EPS Growth, Price/Book.

Bull Case : NOW

The strongest argument for NOW centers on Market Cap, Debt/Equity, Revenue Growth. Revenue growth of 22.1% demonstrates continued momentum. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bear Case : DBD

The primary concerns for DBD are P/E Ratio, Altman Z-Score, Profit Margin. Thin 2.8% margins leave little buffer for downturns.

Bear Case : NOW

The primary concerns for NOW are Price/Book, EPS Growth, Altman Z-Score. A P/E of 64.0x leaves little room for execution misses.

Key Dynamics to Monitor

DBD profiles as a value stock while NOW is a growth play — different risk/reward profiles.

DBD carries more volatility with a beta of 1.11 — expect wider price swings.

NOW is growing revenue faster at 22.1% — sustainability is the question.

NOW generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

DBD scores higher overall (56/100 vs 54/100). NOW offers better value entry with a 83.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Diebold Nixdorf, Incorporated

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Diebold Nixdorf, Incorporated provides connected commerce solutions to financial institutions and retailers in Western Europe, Eastern Europe, Asia, the Middle East, Africa, the United States, Canada, Mexico and Latin America. The company is headquartered in North Canton, Ohio.

ServiceNow Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

ServiceNow is an American software company based in Santa Clara, California that develops a cloud computing platform to help companies manage digital workflows for enterprise operations.

Want to dig deeper into these stocks?